Trial Profile
Study of Omalizumab in Moderate to Severe Bronchial Asthma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Sep 2019
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis
- 24 Oct 2011 Daiichi Sankyo added as company as reported by ClinicalTrials.gov.
- 24 Oct 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
- 05 Nov 2010 New trial record.